Twist Bioscience Corp
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
TWST$132.13-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
| Three months ended March 31, | Six months ended March 31, | |||
|---|---|---|---|---|
| (In thousands, except per share data) | 2026 | 2025 | 2026 | 2025 |
| Revenues[1] | $110,715 | $92,793 | $214,413 | $181,506 |
| Costs and expenses: | ||||
| Cost of revenues | $53,593 | $46,765 | $103,319 | $92,638 |
| Research and development expenses | 19,695 | 23,917 | 36,825 | 45,224 |
| Selling, general and administrative expenses[1] | 76,085 | 63,671 | 145,827 | 119,849 |
| Litigation settlement costs, net of recoveries | 7,205 | — | 7,205 | — |
| Total costs and expenses | $156,578 | $134,353 | $293,176 | $257,711 |
| Loss from operations | $(45,863) | $(41,560) | $(78,763) | $(76,205) |
| Interest income | 1,710 | 2,801 | 3,885 | 6,041 |
| Other income (expense), net[1] | 175 | (394) | 646 | (487) |
| Loss before income taxes | $(43,978) | $(39,153) | $(74,232) | $(70,651) |
| Income tax expense | (43) | (175) | (296) | (271) |
| Net loss | $(44,021) | $(39,328) | $(74,528) | $(70,922) |
| Other comprehensive loss: | ||||
| Change in unrealized gain (loss) on investments | $(85) | $30 | $(67) | $97 |
| Foreign currency translation adjustment | 17 | (25) | 55 | 43 |
| Comprehensive loss | $(44,089) | $(39,323) | $(74,540) | $(70,782) |
| Net loss per share — basic and diluted | $(0.71) | $(0.66) | $(1.21) | $(1.19) |
| Weighted average shares used in computing net loss per share — basic and diluted | 61,702 | 59,649 | 61,387 | 59,403 |
[1]Includes related party balances, see Note 12 - Related Party Transactions.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.